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Asthma
AbstrAct
Introduction Quantitative CT (QCT) imaging-based 
metrics have quantified disease alterations in asthma 
and chronic obstructive pulmonary disease (COPD), 
respectively. We seek to characterise the similarity 
and disparity between these groups using QCT-derived 
airway and parenchymal metrics.
Methods Asthma and COPD subjects (former-smoker 
status) were selected with a criterion of post-
bronchodilator FEV1 <80%. Healthy non-smokers were 
included as a control group. Inspiratory and expiratory 
QCT images of 75 asthmatic, 215 COPD and 94 
healthy subjects were evaluated. We compared three 
segmental variables: airway circularity, normalised 
wall thickness and normalised hydraulic diameter, 
indicating heterogeneous airway shape, wall thickening 
and luminal narrowing, respectively. Using an image 
registration, we also computed six lobar variables 
including per cent functional small-airway disease, 
per cent emphysema, tissue fraction at inspiration, 
fractional-air-volume change, Jacobian and  
functional metric characterising anisotropic  
deformation.
results Compared with healthy subjects, both asthma 
and COPD subjects demonstrated a decreased airway 
circularity especially in large and upper lobar airways, 
and a decreased normalised hydraulic diameter in 
segmental airways. Besides, COPD subjects had more 
severe emphysema and small-airway disease, as well 
as smaller regional tissue fraction and lung deformation, 
compared with asthmatic subjects. The difference of 
emphysema, small-airway disease and tissue fraction 
between asthma and COPD was more prominent in 
upper and middle lobes.
conclusions Patients with asthma and COPD, with a 
persistent FEV1 <80%, demonstrated similar alterations 
in airway geometry compared with controls, but different 
degrees of alterations in parenchymal regions. Density-
based metrics measured at upper and middle lobes were 
found to be discriminant variables between patients with 
asthma and COPD. 
IntroductIon
Asthma is a disease with functional airway 
reversibility through the aid of inhaled corti-
costeroids and bronchodilator, whereas 
chronic obstructive pulmonary disease 
(COPD) is a disease with persistent airflow 
limitation.1–3 According to recent reports,4 5 
around 15%–45% of patients with COPD may 
have asthma–COPD overlap, so-called ACO. 
In previous studies,6 7 some asthmatic patients 
were of neutrophilic dominance with chronic 
airway functional alteration, while some 
patients with COPD were of eosinophilic domi-
nance with airway reversibility.8 9 Thus, objec-
tive differentiation of the two populations is 
essential for proper treatments. Meanwhile, 
two National Institutes of Health (NIH)-sup-
ported multicentre studies, SubPopulations 
and InteRmediate Outcome Measures In 
COPD Study (SPIROMICS)10 and Severe 
Asthma Research Program (SARP),11 have 
been established to identify genetic, environ-
mental and clinical phenotypes for COPD and 
asthma, respectively. SARP excluded patients 
with a smoking history, while SPIROMICS, 
Key messages
 ►  We demonstrate similarity and disparity of 
structure and function between patients with 
asthma and chronic obstructive pulmonary disease 
(COPD) with chronic functional alteration using 
sensitively measured imaging metrics.
 ► Image-derived functional alterations of asthmatics 
were regionally prominent in lower lobes, while 
those of patients with COPD were found in whole 
lungs.
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except healthy subjects, excluded never-smokers. By the 
study designs, the recruited subjects are less likely to be 
ACO. With these populations, we pursue to investigate 
the imaging-based similarity and disparity between two 
respiratory diseases.
Quantitative CT (QCT) imaging has successfully iden-
tified unique structural and functional phenotypes for 
asthma and COPD, respectively. For instance, Aysola 
et al12 found that asthmatics had an increase of wall area 
percentage depending on severity, and Busacker et al13 
found an increase of air trapping in severe asthmatics. 
Using the same imaging datasets from SARP, Choi et al14 15 
demonstrated that existing imaging-based metrics were 
problematic due to intersubject and intersite variability, 
resulting in inaccurate estimation. To address these issues, 
they developed a new air-trapping measure and new 
normalisation schemes for luminal hydraulic diameter 
and wall thickness.14 15 These studies demonstrated that 
on average severe asthmatics were characterised by airway 
narrowing, wall thickening and air trapping. In addition, 
with an image registration technique, they demonstrated 
regional alterations of deformational metrics in severe 
asthmatics.16 The sensitive imaging-based metrics derived 
from multiple studies were then integrated to identify 
clinically meaningful subgroups of asthma.17
In patients with COPD, structural and functional alter-
ations have been assessed by QCT imaging-based vari-
ables including luminal diameter,18 wall thickness,19 air 
trapping (or functional small-airway disease) and emphy-
sema. Existing assessment of air trapping in COPD was also 
problematic because air trapping at expiration contains 
some portion of emphysema at inspiration. Therefore, 
Galban et al20 employed an image registration technique 
to dissociate the portion of emphysema from air trap-
ping, allowing for characterisation of three subgroups, 
that is, emphysema-dominant, functional small-airway 
disease-dominant and normal groups. In addition to the 
CT density mapping, image registration provided local 
deformational metrics including air-volume change, the 
determinant of Jacobian (Jacobian; a measure of volume 
change), anisotropic deformation index (ADI; a measure 
of the magnitude of directional preference in volume 
change), slab rod index (a measure of the nature of direc-
tional preference in volume change) and more.21 Boddu-
luri et al22 used the image registration metrics to perform 
a supervised learning for the purpose of distinguishing 
patients with COPD from non-COPD subjects. Further, 
Smith et al19 compared wall thicknesses of patients with 
COPD and non-COPD subjects, and found thinner airway 
walls in patients with COPD than non-COPD subjects 
when wall thickness is compared at the same location.
QCT imaging-based variables have been employed in 
a variety of studies to identify local or global alterations 
in airway dimension and lobar function. Although there 
are several studies to compare airway structure or lung 
function between asthma and COPD,23–25 the numbers 
of subjects under investigation were limited. Therefore, 
this study aims to investigate the similarity and disparity 
between large cohorts of asthma and COPD subjects 
acquired from SARP and SPIROMICS, especially those 
with overlapping clinical symptoms of chronic functional 
alterations measured by post-bronchodilator FEV1 <80%. 
In order to assess structure and function at global and 
lobar levels, we employed multiscale imaging-based vari-
ables,14–17 including local airway structural variables at 
inspiration scan, and lobar/global functional variables at 
expiration scan. We further employed image registration 
metrics including Jacobian, ADI and functional small-
airway disease percentage (fSAD%) and emphysematous 
lung percentage (Emph%).
Methods
Inclusion criteria and Qct imaging data
We employed QCT imaging data from SARP and SPIRO-
MICS. Both populations used a similar imaging protocol 
which has been described by Sieren et al26 and were 
approved by the respective institutional review boards. 
We selected subjects who demonstrated post-bronchodi-
lator FEV1 %predicted values <80% to focus on subjects 
with airflow obstruction. In SARP data, none of the 
asthmatics were current smokers as one of the inclusion 
criteria was ‘no smoking within the past five years and <5 
pack-years of smoking’.27 SPIROMICS, except for healthy 
controls, excluded non-smokers, and in this study only 
former smokers were included using the criterion of ‘not 
currently smoking as of 1 month ago’.10 The numbers 
of asthmatic and COPD subjects meeting these criteria 
were 75 and 215. In addition, 94 healthy subjects without 
smoking history including 51 SARP and 43 SPIROMICS 
subjects were used as a control group (table 1). There 
are more imaging data in SARP and SPIROMICS, but 
the imaging data from eight SPIROMICS and three 
SARP centres were only used in this study (table 2). 
The imaging data from SARP were previously employed 
to identify imaging-based asthma clusters.17 All of the 
imaging centres acquired inspiratory and expiratory QCT 
scans for each subject. While both SPIROMICS and SARP 
obtained inspiration scans at TLC, expiration scans were 
obtained at functional residual capacity (FRC) for SARP 
and residual volume (RV) for SPIROMICS. Thus, caution 
must be taken in interpreting results associated with 
expiration scan and volumetric difference. For instance, 
fSAD% and Jacobian may increase and decrease respec-
tively by using FRC rather than RV scans.
An expanded set of multiscale imaging-based variables
We employed a total of 67 imaging-based metrics, where 
55 of them were multiscale imaging-based metrics devel-
oped for the asthma cluster analysis.17 Using Apollo 
(VIDA Diagnostics),28 we derived three local structural 
variables: airway circularity (Cr), wall thickness (WT) 
and hydraulic diameter (Dh) extracted at total lung 
capacity (TLC) scans. WT and Dh were normalised 
with the tracheal WT and Dh predicted from healthy 
subjects, denoted as WT* and Dh*.
14 Cr, WT* and Dh* 
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indicate heterogeneous airway shape, airway wall thick-
ening and airway luminal narrowing, respectively. A 
detailed description of airway-structural imaging metrics 
can be found in ref.14 Furthermore, for the compar-
ison with patients with COPD, we used the parametric 
response map20 to subtract the emphysematous lung 
regions from regions labelled as air trapped on expir-
atory scans using an image registration technique,29 
being denoted as fSAD%. We also added two more 
variables: Emph% and tissue fraction at TLC (βtissue). 
Rather than the CT density-threshold method, we used a 
fraction-threshold method to determine fSAD% (air 
fraction, βair >90%) and Emph% (βair >98.5%), elimi-
nating intersite variability.15 Next, βtissue was computed 
by the portion of tissue volume in a voxel to evaluate an 
alteration of local tissue. Furthermore, we computed frac-
tional lobar air-volume change (ΔVair
f), Jacobian and ADI 
via image registration.16 17 ΔVair
f, Jacobian and ADI indi-
cated preferential lobar air-volume change (a measure 
of regional ventilation), local expansion (a measure of 
regional volume change) and non-uniform stretch (a 
measure of the magnitude of direction preference in 
volume change), respectively, in parenchymal regions. 
A detailed description of functional imaging metrics is 
available in refs.16 17
statistical analysis
Kruskal-Wallis and χ2 test30 were performed to compare 
differences of continuous and categorical variables 
between healthy, asthmatic and COPD subjects. We 
performed a total of 87 comparison tests, and a P value 
of 0.01 was taken as the significant level in all tests. This 
controls the false discovery rate of multiple comparisons 
at 1%, as estimated by using the method of Benjamin and 
Hochberg.31
results
demography, PFts and blood tests
Table 1 shows demography, pre-bronchodilator and 
post-bronchodilator pulmonary function test (PFT) 
and blood test results among three populations, that 
is, healthy subjects, patients with asthma and patients 
with COPD. Ages of patients with COPD were greater 
than those of healthy and asthmatic subjects, and the 
portion of female sex was similar between asthma (47%) 
Table 1 Demographic, pre-bronchodilator and post-bronchodilator pulmonary function tests, blood inflammatory information 
among healthy subjects, patients with asthma and patients with chronic obstructive pulmonary disease (COPD)
Healthy subjects 
(n=94§)
Patients with asthma 
(n=75)
Patients with COPD 
(n=215)
Demography
  Age (years) 50.7 (17.2) 48.7 (11.2) 67.1 (7.2)†‡
  Female sex (%) 59 47 41
  Body mass index (kg/m2) 27.7 (5.5) 33.5 (7.5)* 27.9 (4.9)†
  Race (white/African-American/other) (%) 65/20/15 76/17/7 87/7/6‡
Pre-bronchodilator
  FEV1, %predicted 98 (12) 53 (14)* 44 (18)†‡
  FVC, %predicted 98 (10) 69 (13)* 76 (17) †‡
  FEV1/FVC 79 (6) 61 (11)* 43 (13)†‡
Post-bronchodilator
  FEV1, %predicted 103 (11) 65 (11)* 51 (19)†‡
  FVC, %predicted 99 (10) 80 (14)* 85 (18)‡
  FEV1/FVC 82 (6) 65 (11)* 45 (13)†‡
Blood tests
  Samples (n) 93 73 213
  Total white blood cells (N/μL) 5894 (1717) 7902 (2962)* 7247 (1999)‡
  Neutrophils (%) 58.1 (7.8) 59.2 (12.4) 63.3 (9.7)‡
  Lymphocytes (%) 31.7 (7.4) 28.2 (10.5) 24.6 (8.3)‡
  Eosinophils (%) 2.3 (1.6) 3.9 (3.7)* 2.9 (1.8)‡
*P<0.01 for healthy versus asthmatic subjects.
†P<0.01 for asthmatic versus COPD subjects.
‡P<0.01 for COPD subjects versus healthy subjects.
§Healthy datasets contain 51 Severe Asthma Research Program and 43 SubPopulations and InteRmediate Outcome Measures In COPD 
Study subjects. Benjamini–Hochberg post-hoc tests were performed.
FEV1, Forced expiratory volume in one second; FVC, Forced vital capacity.
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and COPD (41%). Asthmatic patients were more obese 
than healthy subjects and patients with COPD, whereas 
there was a lower portion of African-Americans in COPD. 
Compared with healthy subjects, both asthmatic patients 
and patients with COPD had lower FEV1 and FVC 
%predicted values according to their inclusion criteria 
with FEV1 %predicted value <80%. Pre-bronchodilator 
FEV1 %predicted values of patients with COPD were 
lower than those of asthma, while FVC % predicted values 
of patients with COPD were greater than those of asthma, 
leading to a further reduction of FEV1/FVC in patients 
with COPD. Thus, at pre-bronchodilator, flow restric-
tion and obstruction were dominant for asthma and 
COPD, respectively. At post-bronchodilator, the differ-
ence between FEV1 %predicted values for asthma and 
COPD were more significant, whereas FVC %predicted 
values were close for both populations due to the func-
tional reversibility of asthma. We further compared blood 
inflammatory biomarkers. Both patients with asthma and 
COPD demonstrated greater numbers of white blood cell 
counts than those of healthy subjects. The percentages of 
neutrophils and lymphocytes increased and decreased in 
patients with COPD, respectively, compared with those of 
healthy and asthmatic subjects. The percentages of eosin-
ophils in both asthma and COPD were elevated, relative 
to that of healthy subjects.
central airway-structural characteristics
Figure 1 shows regional difference of Cr, WT* and Dh* 
among healthy, asthmatic and COPD subjects. For a 
better presentation, we divided 10 local branches into 
two regions (top vs bottom columns), that is, five central 
airways (trachea, right main bronchus (RMB), left main 
bronchus (LMB), right intermediate bronchus (BronInt) 
and trifurcation of left lower lobe (TriLLB)), and five 
segmental airways (subgrouped left upper lobe (sLUL), 
subgrouped right upper lobe (sRUL), subgrouped right 
middle lobe (sRML), subgrouped left lower lobe (sLLL) 
and subgrouped right lower lobe (sRLL)). Cr signifi-
cantly decreased in both asthmatic patients and patients 
with COPD compared with healthy subjects especially 
in central airways, where COPD decreased more than 
asthma in trachea and BronInt (figure 1A). In segmental 
airways, Cr of healthy subjects versus patients with COPD 
was only different in upper and middle lobes (see sLUL, 
sRUL and sRML in figure 1B). WT* of COPD subjects 
increased only in trachea compared with healthy subjects 
(figure 1C), while it decreased in sLUL and sRML of 
patients with COPD (figure 1D). Other than these three 
regions, there was no noticeable difference of WT* 
among three populations. There was no difference of Dh* 
in trachea and LMB, whereas Dh* of patients with asthma 
and COPD significantly decreased in other regions except 
these two regions (figure 1E, F). The reduced quantities 
of Dh* in segmental airways between asthma and COPD 
were similar.
Parenchymal functional characteristics
We also compared parenchymal/global functional 
metrics including Emph%, fSAD%, βtissue, ΔVairf, Jacobian 
and ADI (figure 2A–F). The former four variables were 
associated with CT density-based assessment, whereas 
the latter two variables were associated with mechanical 
strains estimated by image registration. As expected, 
Emph% of COPD subjects significantly increased 
compared with those of healthy and asthma subjects, 
and asthma subjects also showed a significant elevation 
of Emph% (figure 2A). fSAD% significantly increased 
in patients with COPD and asthma, especially in patients 
with COPD (figure 2B). Relative to healthy subjects, a 
new variable βtissue at inspiration decreased in entire lungs 
in patients with COPD (figure 2C), possibly due to tissue 
destruction by emphysema. Unlike Emph%, βtissue was 
similar between healthy and asthmatic subjects, whereas 
it decreased only in patients with COPD. ΔVair
f behaved 
similarly in both patients with asthma and COPD, such 
that ΔVair
f increased in RUL and it decreased in right 
lower lobe (RLL) (figure 2D). Thus the relative contri-
bution of air-volume change was shifted from lower and 
middle lobes to upper lobes. Jacobian, indicating local 
volume change, decreased in both disease groups but 
more in patients with COPD (figure 2E). ADI, indicating 
preferential deformation, decreased more in upper lobes 
of COPD subjects, whereas it decreased similarly in lower 
lobes of patients with asthma and COPD (figure 2F). 
This may indicate difference of upper lobar character-
istics in deforming lungs between patients with asthma 
and COPD.
Table 2 The number of quantitative CT imaging datasets 
according to imaging centres: each dataset contains one 
inspiration and one expiration scan
Project Imaging centre (abbreviation)
Number of 
datasets
SubPopulations and InteRmediate Outcome 
Measures In COPD Study (eight sites)
284
Columbia University (CU) 61
Johns Hopkins University (JH) 24




University of Michigan (MU) 39
University of California at San 
Francisco (SF)
31
University of Utah (UT) 59
Wake Forest University (WF) 19
Severe Asthma Research Program (three sites) 100
University of Pittsburgh (PIT) 44
University of Wisconsin (WIS) 38
Washington University in Saint Louis 
(WSL)
18
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dIscussIon
Using QCT imaging-based variables, we have investigated 
the structural and functional characteristics at segmental 
and lobar/global scales between two airway obstructive 
diseases, for example, asthma and COPD. These subjects 
were clinically diagnosed with either asthma or COPD by 
NIH-sponsored multicentre studies of SARP and SPIRO-
MICS. In this study, we compared currently non-smoking 
patients with asthma and former smoker patients with 
COPD with similar clinically overlapping characteristics 
of reduced lung function measured by post-broncho-
dilator FEV1 <80%. Asthma is characterised by airway 
narrowing, wall thickening and air trapping (or func-
tional small-airway disease) and reduced lung deforma-
tion.12–16 COPD is characterised by airway narrowing, air 
trapping, increased emphysematous lung percentage and 
reduced lung deformation.18–20 22 As multicentre studies, 
SARP and SPIROMICS contributed to identify disease 
phenotypes by collecting subject demographics, biospec-
imens, QCTs and other data for patients with asthma and 
COPD. The present study has been able to take unique 
advantage of these multicentre studies with similar 
imaging protocols and similar image analysis, allowing for 
a comparison of the QCT data serving to define asthma 
and COPD imaging phenotypes. A better understanding 
of distinct structural and functional features between 
the two populations may help to develop personalised 
treatment intervention and improve the classification of 
asthma and COPD.
Regarding airway structure, Cr, WT* and Dh* demon-
strated different characteristics from observed features 
in healthy subjects. Cr, indicating the heterogeneous 
distribution of airway shape, was mostly altered in large 
airways and segmental bronchi in upper and middle 
lobes. COPD demonstrated the greater degree of these 
alterations relative to asthma (figure 2A, B). WT* seems 
to be clearly increased only in the trachea of patients with 
COPD compared with healthy patients and patients with 
asthma. The alterations of Cr and WT* in larger airways 
(or lower generations) may indicate that airway remod-
elling due to chronic inflammation or chronic bron-
chitis was predominantly caused in large airways rather 
than small airways. Unlike Cr and WT*, Dh*, indicating 
airway narrowing, was significantly decreased in both 
asthma and COPD to a similar degree compared with 
healthy subjects. We have previously reported that among 
airway structural variables Dh* was the most significantly 
correlated with PFT-based FEV1 and FEV1/FVC.
14 Since 
Figure 1 (A, B) Airway circularity (Cr), (C, D) normalised wall thickness (WT*) and (E, F) normalised hydraulic diameter (Dh*) in 
10 local regions among healthy, asthmatic and chronic obstructive pulmonary disease (COPD) subjects. Values are presented 
as mean (±CI). *P<0.01 for healthy versus asthmatic subjects. †P<0.01 with red-dashed box for asthmatic versus COPD 
subjects. ‡P<0.01 for COPD subjects versus healthy subjects. BronInt, right intermediate bronchus; LMB, left main bronchus; 
RMB, right main bronchus; sLLL, subgrouped left lower lobe; sLUL, subgrouped left upper lobe; sRLL, subgrouped right 
lower lobe; sRML, subgrouped right middle lobe; sRUL, subgrouped right upper lobe; TriLLB, trifurcation of left lower lobe.
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we studied patients with lower FEV1, a smaller Dh* was 
expected. With regard to regional phenotype, as shown 
in figure 2, airway structural alterations estimated by Cr, 
WT* and Dh* were located randomly, implying that each 
metric demonstrates different phenotype.
Compared with airway structural variables, paren-
chymal functional variables provided much clearer differ-
ences between asthma and COPD. Although asthma 
demonstrated an increase of Emph%, which might be 
the result of unmeasurable environmental exposures.32 
As would be expected, we found a significantly greater 
elevation in Emph% in COPD. Although fSAD% is an 
independent variable from Emph%, it exhibited a similar 
pattern with Emph%, such that patients with COPD had 
a greater elevation of fSAD% than asthma. While Dh* had 
similar values between asthma and COPD, fSAD%, indi-
cating small-airway disease, had significantly different 
values between asthma and COPD. This may indicate that 
small airway disease in patients with COPD is more prom-
inent than asthmatic subjects. In other words, asthma 
reversibility is an effect predominantly localised to the 
peripheral airways as demonstrated by Verbanck et al.33 34 
In this study, we also introduced a new variable βtissue to 
evaluate the state of tissue alteration.35 A decrease of βtissue 
is possibly related to tissue destruction due to emphy-
sema. Thus, βtissue can serve as a metric used to differ-
entiate between asthma, COPD and healthy subjects in 
addition to Emph% and fSAD%.
Using an image registration technique, we derived 
ΔVair
f, Jacobian and ADI. ΔVair
f, indicating regional distri-
bution of air-volume change, seemed to increase in RUL 
and decrease in RLL consistently in asthma and COPD 
subjects. The similar finding has been reported in our 
previous study with 30 severe asthmatics.16 17 Jacobian, 
indicating the degree of local deformation, was signifi-
cantly reduced in both asthma and COPD, with a more 
Figure 2 (A) Percentage of emphysematous lung (Emph%), (B) functional small airway disease (fSAD%), (C) tissue 
fraction at inspiration (βtissue), (D) fractional lobar air-volume change (ΔVairf), (E) the determinant of Jacobian (Jacobian) and (F) 
anisotropic deformation index (ADI) among healthy, asthmatic and chronic obstructive pulmonary disease (COPD) subjects. 
Values are presented as mean (±CI). *P<0.01 for healthy versus asthmatic subjects. †P<0.01 with red-dashed box for 
asthmatic versus COPD subjects. ‡P<0.01 for COPD subjects versus healthy subjects. LLL, left lower lobe; LUL, left upper 
lobe; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe.
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severe reduction in COPD. ADI seemed to have different 
characteristics from Jacobian in that it decreased in lower 
lobes for both asthma and COPD. On the other hand, it 
seemed to be relatively normal in RUL and RML in asth-
matics, unlike patients with COPD. Based on ΔVair
f and 
ADI, functional alterations of asthmatics were observed 
more in lower lobes, whereas those of COPD were 
observed in entire lungs.
When comparing multicentre data, it is necessary to 
use standardised imaging protocols. Since this study is 
designed retrospectively, there were protocol differ-
ences. The most critical difference between SARP and 
SPIROMICS is about lung volume when obtaining 
expiratory scans. SARP took expiratory scans at FRC, 
whereas SPIROMICS did this at RV. Thus COPD subjects 
obtained from SPIROMICS should have larger Jacobian 
and smaller fSAD% because RV is smaller lung volume 
than FRC. Nevertheless, the results showed that COPD 
subjects had significantly smaller Jacobian and larger 
fSAD% than asthmatic subjects which likely go beyond 
differences that would be expected from imaging at RV 
versus FRC. Therefore, the actual difference between 
asthma and COPD should be greater than that reported 
here if the same imaging protocol were used. It also 
should be noted that obesity in asthmatics may reduce 
expiratory reserve volume, making FRC closer to RV.36 
Furthermore, due to the disease features, asthma is likely 
to be early onset, whereas COPD is likely to be late onset. 
Asthma is also associated with obesity, whereas COPD is 
with loss of weight. These disease features prevent from 
matching their demographics. Another issue may be 
raised due to intersubject variability including sex, age 
and height. We previously found that sex is the most 
important metric to determine airway size including 
hydraulic diameter and wall thickness; therefore, we 
developed new normalisation schemes to control the 
intersubject variability. Furthermore, there was no bias 
of samples due to the female sex between asthma and 
COPD (table 1).
In conclusion, QCT imaging-based variables were found 
to be effective in differentiating asthmatics from healthy 
subjects as well as COPD subjects from asthma subjects. 
Both asthma and COPD had a decrease of airway luminal 
circularity particularly in larger airways and a decrease 
of hydraulic diameter in segmental airways to the same 
degree. Functional metrics, especially density-based 
metrics, obtained at lobar/global regions were found to 
be significantly different between the two disease popu-
lations. Compared with asthma, COPD has significantly 
more lung emphysema, more small-airway disease, with 
reduced tissue fraction and regional lung deforma-
tion. Regionally, functional alterations of asthmatics 
were prominent in lower lobes, while those of patients 
with COPD were found in whole lungs. Based on these 
functional and regional features, density-based metrics 
including tissue fraction, fSAD% and Emph% measured 
at parenchymal levels were found to be important in 
differentiating patients with asthma and COPD.
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